Trials / Completed
CompletedNCT01883388
NovellusDx Cancer Early Detection Blood Test- Clinical Trial
Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Fore Biotherapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
NovellusDx early detection test is a simple to perform blood test, which identifies the deregulated signaling pathways within the patient tumor based on protein secretion to the blood, thus enabling early stage disease signature detection. The investigators' current clinical trial is focused on proving the main feature of NovellusDx's Early Detection Test- discriminating between cancer patients and healthy subjects.
Conditions
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2016-12-01
- First posted
- 2013-06-21
- Last updated
- 2018-03-29
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01883388. Inclusion in this directory is not an endorsement.